A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinomaWu‐tong Ju, Lai‐ping Zhong|Nature Communications|2022Cited by 119